OptumHealth Education Video Podcast Series
By OptumHealth Education
To listen to an audio podcast, mouse over the title and click Play. Open iTunes to download and subscribe to podcasts.
Podcast Description
OptumHealth Education (formerly i3 CME), an accredited provider of continuing medical education, is dedicated to improving patient care and health outcomes through the education of health care professionals. We apply standards of excellence to designing, delivering and assessing the impact of evidence-based, independent, certified educational activities. We combine evidence-based medicine and adult learning principles with dynamic multimedia technology and innovative delivery formats to appeal to the diverse learning preferences and educational needs of health care professionals across multiple therapeutic areas. OptumHealth Education delivers more than 600 CME activities to more than 35,000 health care professionals each year. At OptumHealth Education, we integrate medical expertise and adult learning principles with dynamic technology to deliver compelling CME programming to health care professionals in a variety of formats. Using evidence-based and scientifically rigorous CME content, merged with medical and pharmacy claims data assets, we increase our ability to assess the impact of our CME activities with exceptional precision and unparalleled effectiveness.
| Name | Description | Released | Price | ||
|---|---|---|---|---|---|
| 1 | Early Recognition and Treatment of Bipolar Disorder: Preclinical Evidence of a Neuroprotective Effect and Empirical Evidence fo | This simulcast will review evidence suggesting that subsyndromal depression is associated with eventual development of bipolar disorder. The activity will incorporate evidence for the proposed neuroprotective effects of atypicals and the suggestion that earlier and aggressive treatment is important. Expert faculty will also have the opportunity to debate the pros and cons of early intervention with pharmacologic treatment of subsyndromal depressive symptoms, particularly those in children, adolescents, and young adults. They will provide evidence for both sides of the argument: 1) the social and occupational impairment associated with symptoms warrants treatment and 2) the risks associated with pharmacologic treatment are not warranted for patients who may not go on to develop bipolar disorder. This program will encourage practitioners to thoroughly consider their treatment options when confronted with this clinical dilemma. | 6/12/08 | Free | View In iTunes |
| 2 | VideoEarly Recognition and Treatment of Bipolar Disorder: Preclinical Evidence of a Neuroprotective Effect and Empirical Evidence fo | This simulcast will review evidence suggesting that subsyndromal depression is associated with eventual development of bipolar disorder. The activity will incorporate evidence for the proposed neuroprotective effects of atypicals and the suggestion that earlier and aggressive treatment is important. Expert faculty will also have the opportunity to debate the pros and cons of early intervention with pharmacologic treatment of subsyndromal depressive symptoms, particularly those in children, adolescents, and young adults. They will provide evidence for both sides of the argument: 1) the social and occupational impairment associated with symptoms warrants treatment and 2) the risks associated with pharmacologic treatment are not warranted for patients who may not go on to develop bipolar disorder. This program will encourage practitioners to thoroughly consider their treatment options when confronted with this clinical dilemma. | 6/12/08 | Free | View In iTunes |
| 3 | VideoHow Far Have We Come? Issues in Adherence to Antidepressant Treatment: Focus on Tolerability and Quality of Life | Although depression is a common occurrence, its diagnosis is estimated to occur accurately in only one half of all who suffer from this disorder. Achieving remission with effective yet tolerable treatments may improve the quality of life of patients suffering from depression. However, studies show that the average length of antidepressant treatment is less than 6 months and that discontinuation rates are most frequent during the first month of therapy. Factors leading to treatment discontinuation are multiple and poorly understood. Important treatment decisions should involve utilizing antidepressants with low side effect profiles, with the goal of minimizing nonadherence. Early treatment leads to more rapid resolution of symptoms and, ultimately, a more favorable outcome. Because many differences exist among pharmacologic treatments, it is important for clinicians to select tolerable and safe first-line treatments that will encourage adherence. Additionally, recent research reveals that the clinician’s attitude about medication and even the clinician-patient relationship, including the amount of time the clinician takes to explain the expected duration of treatment and possible adverse effects, are key factors for therapeutic adherence. Strategies should be adapted to the stage of treatment, as common reasons for discontinuation change as treatment progresses. | 12/18/07 | Free | View In iTunes |
| 4 | How Far Have We Come? Issues in Adherence to Antidepressant Treatment: Focus on Tolerability and Quality of Life - Activity Pac | Although depression is a common occurrence, its diagnosis is estimated to occur accurately in only one half of all who suffer from this disorder. Achieving remission with effective yet tolerable treatments may improve the quality of life of patients suffering from depression. However, studies show that the average length of antidepressant treatment is less than 6 months and that discontinuation rates are most frequent during the first month of therapy. Factors leading to treatment discontinuation are multiple and poorly understood. Important treatment decisions should involve utilizing antidepressants with low side effect profiles, with the goal of minimizing nonadherence. Early treatment leads to more rapid resolution of symptoms and, ultimately, a more favorable outcome. Because many differences exist among pharmacologic treatments, it is important for clinicians to select tolerable and safe first-line treatments that will encourage adherence. Additionally, recent research reveals that the clinician’s attitude about medication and even the clinician-patient relationship, including the amount of time the clinician takes to explain the expected duration of treatment and possible adverse effects, are key factors for therapeutic adherence. Strategies should be adapted to the stage of treatment, as common reasons for discontinuation change as treatment progresses. | 12/18/07 | Free | View In iTunes |
| 5 | VideoNovel Approaches to the Treatment of Major Depressive Disorder: Beyond SSRIs and SNRIs | Although SSRIs are often effective in the treatment of MDD, their limitations and unique side effect profiles restrict routine use in all patients. SNRIs, TCAs, and first-generation MAOIs are not commonly used due to their side effect profiles. Atypical antipsychotics, with their milder side effect profiles, are emerging as beneficial augmentation therapy for patients with treatment-resistant depression without psychotic features. Advances in treatment include the MAOI-B inhibitor transdermal selegiline, which may also have efficacy in treatment-resistant depression (TRD) as well as a favorable side effect profile in treatment-responsive patients in the prevention of relapse. Duloxetine has been well demonstrated in the acute and long-term treatment of MDD, and agomelatine (a melatonergic agonist and 5-HT2C antagonist) appears to be an effective antidepressant comparable to standard SSRI/SNRI drugs with an excellent safety and tolerability profile. The olanzapine/fluoxetine combination has shown rapid, robust, and sustained improvement in depressive symptoms in patients with MDD, including patients with TRD. | 11/13/07 | Free | View In iTunes |
| 6 | Novel Approaches to the Treatment of Major Depressive Disorder: Beyond SSRIs and SNRIs - Activity Packet | Although SSRIs are often effective in the treatment of MDD, their limitations and unique side effect profiles restrict routine use in all patients. SNRIs, TCAs, and first-generation MAOIs are not commonly used due to their side effect profiles. Atypical antipsychotics, with their milder side effect profiles, are emerging as beneficial augmentation therapy for patients with treatment-resistant depression without psychotic features. Advances in treatment include the MAOI-B inhibitor transdermal selegiline, which may also have efficacy in treatment-resistant depression (TRD) as well as a favorable side effect profile in treatment-responsive patients in the prevention of relapse. Duloxetine has been well demonstrated in the acute and long-term treatment of MDD, and agomelatine (a melatonergic agonist and 5-HT2C antagonist) appears to be an effective antidepressant comparable to standard SSRI/SNRI drugs with an excellent safety and tolerability profile. The olanzapine/fluoxetine combination has shown rapid, robust, and sustained improvement in depressive symptoms in patients with MDD, including patients with TRD. | 11/13/07 | Free | View In iTunes |
| 7 | VideoAddressing the Socioeconomic Impact of Depression and Comorbid Medical Illness in the Primary Care Setting | Long-term management strategies for the treatment of depression and comorbid medical conditions should optimize effective therapies that target patient-specific symptoms of both depression and other illnesses, while minimizing side effects that may impede medication adherence and patient outcomes. As a result, clinicians need to understand the role of the latest treatment options, their use in long-term management of overall patient health and quality of life, and the impact of continuity of care from the disease state management/cost effectiveness perspective. Part of the problem is that mental health issues are separated clinically—and paid for separately—from physical health issues. Progress depends on changing this attitude via better integration of primary care, psychiatric, and managed care needs and improved utilization of employee assistance programs. | 11/8/07 | Free | View In iTunes |
| 8 | Addressing the Socioeconomic Impact of Depression and Comorbid Medical Illness in the Primary Care Setting - Activity Packet | Long-term management strategies for the treatment of depression and comorbid medical conditions should optimize effective therapies that target patient-specific symptoms of both depression and other illnesses, while minimizing side effects that may impede medication adherence and patient outcomes. As a result, clinicians need to understand the role of the latest treatment options, their use in long-term management of overall patient health and quality of life, and the impact of continuity of care from the disease state management/cost effectiveness perspective. Part of the problem is that mental health issues are separated clinically—and paid for separately—from physical health issues. Progress depends on changing this attitude via better integration of primary care, psychiatric, and managed care needs and improved utilization of employee assistance programs. | 11/8/07 | Free | View In iTunes |
| 9 | Ethnicity, Cultural Competence, and Medication Adherence: Understanding the Issues - Activity Packet | Many persons suffering from long-term mental disorders experience relapses and illness exacerbations that are related to medication nonadherence. Adherence to prescribed medications is a universal value for clinicians, yet the factors contributing to such nonadherence are poorly understood. Given the ever-increasing diversity of the United States, understanding ethno-cultural differences are particularly important in psychiatry. This activity will explore how ethnicity and cultural competence impacts medication adherence in mentally ill patients. | 9/18/07 | Free | View In iTunes |
| 10 | VideoEthnicity, Cultural Competence, and Medication Adherence: Understanding the Issues | Many persons suffering from long-term mental disorders experience relapses and illness exacerbations that are related to medication nonadherence. Adherence to prescribed medications is a universal value for clinicians, yet the factors contributing to such nonadherence are poorly understood. Given the ever-increasing diversity of the United States, understanding ethno-cultural differences are particularly important in psychiatry. This activity will explore how ethnicity and cultural competence impacts medication adherence in mentally ill patients. | 9/18/07 | Free | View In iTunes |
| 11 | VideoCase Studies in Bipolar Depression: Best Practices for the Hospitalized Patient | There is tremendous complexity in the various symptoms and behavioral dimensions associated with bipolar depressive disorder (BDD). The best practices for treating these complexities are derived from research findings, clinical experiences, and the consensus of experts. This activity, the second in a series of two, will demonstrate through challenging case examples the best practices for the varying clinical states of BDD. Specifically, experts will discuss the intricacies of treating and managing the outpatient at risk for a depressive relapse. | 7/24/07 | Free | View In iTunes |
| 12 | Case Studies in Bipolar Depression: Best Practices for the Hospitalized Patient - Activity Packet | There is tremendous complexity in the various symptoms and behavioral dimensions associated with bipolar depressive disorder (BDD). The best practices for treating these complexities are derived from research findings, clinical experiences, and the consensus of experts. This activity, the second in a series of two, will demonstrate through challenging case examples the best practices for the varying clinical states of BDD. Specifically, experts will discuss the intricacies of treating and managing the outpatient at risk for a depressive relapse. | 7/24/07 | Free | View In iTunes |
| 13 | VideoDiagnostic and Management Challenges in Major Depression: New Treatment Strategies | Major depression is one of the most common psychiatric illnesses in the adult population. The disorder, unfortunately, continues to remain underdiagnosed and remission rates remain low. While many pharmacologic treatment options are available, up to one third of patients may discontinue treatment within one month after the initial prescription. This is alarming as treatment adherence is essential to achieving and maintaining remission. This educational activity will review the importance of minimizing side effects of pharmacologic treatments and maximizing adherence, thus, working to attain remission of the illness. | 7/17/07 | Free | View In iTunes |
| 14 | Diagnostic and Management Challenges in Major Depression: New Treatment Strategies - Activity Packet | Major depression is one of the most common psychiatric illnesses in the adult population. The disorder, unfortunately, continues to remain underdiagnosed and remission rates remain low. While many pharmacologic treatment options are available, up to one third of patients may discontinue treatment within one month after the initial prescription. This is alarming as treatment adherence is essential to achieving and maintaining remission. This educational activity will review the importance of minimizing side effects of pharmacologic treatments and maximizing adherence, thus, working to attain remission of the illness. | 7/17/07 | Free | View In iTunes |
| 15 | Clinical Debate: Are Some Antipsychotics More Effective Than Others - Activity Packet | This activity seeks to provide a clear and concise description and summary of the existing evidence base for antipsychotic agent use that includes 2 influential pragmatic national trials eg, CATIE and CUtLASS. The relevance of these findings to clinical practice will be demonstrated through the use of a debate format, including discussion on the development of risk-benefit assessments for the use of antipsychotic agents in the clinical practice setting. The debate format constitutes an extremely effective educational tool when the theme (in this case, comparative effectiveness among antipsychotic medications) is fraught with controversy. The presentation of “pro” and “con” perspectives is an effective method of translating evidence and expert opinion into practice. | 5/17/07 | Free | View In iTunes |
| 16 | VideoClinical Debate: Are Some Antipsychotics More Effective Than Others | This activity seeks to provide a clear and concise description and summary of the existing evidence base for antipsychotic agent use that includes 2 influential pragmatic national trials eg, CATIE and CUtLASS. The relevance of these findings to clinical practice will be demonstrated through the use of a debate format, including discussion on the development of risk-benefit assessments for the use of antipsychotic agents in the clinical practice setting. The debate format constitutes an extremely effective educational tool when the theme (in this case, comparative effectiveness among antipsychotic medications) is fraught with controversy. The presentation of “pro” and “con” perspectives is an effective method of translating evidence and expert opinion into practice. | 5/17/07 | Free | View In iTunes |
| 17 | VideoPharmacodynamics of Atypical Antipsychotics: Sedation Versus Efficacy | The understanding that sedation is no longer considered an important aspect of medication efficacy is leading to a paradigm shift in the way patients with serious mental illness should be treated. | 5/15/07 | Free | View In iTunes |
| 18 | Pharmacodynamics of Atypical Antipsychotics: Sedation Versus Efficacy - Activity Packet | The understanding that sedation is no longer considered an important aspect of medication efficacy is leading to a paradigm shift in the way patients with serious mental illness should be treated. This 1-hour educational activity will provide up-to-date information regarding pharmacology of first-line antipsychotics, side effect profiles, and the impact of medication on treatment and treatment guidelines as they relate to acute and behavioral emergencies and the issue of sedation. | 5/15/07 | Free | View In iTunes |
| 19 | VideoReal-World Challenges in Cardiovascular Disease: Aggressive Management of Patients with Diabetes and Dyslipidemia | Despite the large burden of cardiovascular disease on society, abnormal lipid levels are not being adequately managed in many individuals, particularly those with type 2 diabetes mellitus. The management of these patients is complex and many are not receiving appropriate lipid-lowering therapy. One of the major challenges to improving the care of patients with diabetes and dyslipidemia includes the implementation of proven therapies in this patient population. This activity will provide a forum to discuss necessary lipid reductions, available therapies, appropriate treatment regimens, and optimal efficacy and safety monitoring in patients with diabetes and dyslipidemia. | 4/26/07 | Free | View In iTunes |
| 20 | Real-World Challenges in Cardiovascular Disease: Aggressive Management of Patients with Diabetes and Dyslipidemia - Activity Pa | Despite the large burden of cardiovascular disease on society, abnormal lipid levels are not being adequately managed in many individuals, particularly those with type 2 diabetes mellitus. The management of these patients is complex and many are not receiving appropriate lipid-lowering therapy. One of the major challenges to improving the care of patients with diabetes and dyslipidemia includes the implementation of proven therapies in this patient population. This activity will provide a forum to discuss necessary lipid reductions, available therapies, appropriate treatment regimens, and optimal efficacy and safety monitoring in patients with diabetes and dyslipidemia. | 4/26/07 | Free | View In iTunes |
| 21 | Strategies for Dosing and Switching Antipsychotics for Optimal Clinical Management - Activity Packet | Due to the growing armamentarium of atypical antipsychotic choices, it is becoming increasingly challenging to select the appropriate therapy. Clinicians must have good understanding of the efficacy of individual atypical antipsychotics and their potential side effects when considering a switch from one atypical to another. This i3 CME activity will examine the clinical evidence and strategies for switching antipsychotic treatments in patients with schizophrenia or bipolar disorder to improve adherence rates, quality of live, and the course of the disease. | 4/24/07 | Free | View In iTunes |
| 22 | VideoStrategies for Dosing and Switching Antipsychotics for Optimal Clinical Management | Due to the growing armamentarium of atypical antipsychotic choices, it is becoming increasingly challenging to select the appropriate therapy. Clinicians must have good understanding of the efficacy of individual atypical antipsychotics and their potential side effects when considering a switch from one atypical to another. This i3 CME activity will examine the clinical evidence and strategies for switching antipsychotic treatments in patients with schizophrenia or bipolar disorder to improve adherence rates, quality of live, and the course of the disease. | 4/24/07 | Free | View In iTunes |
| Total: 22 Episodes |
Viewers also subscribed to
- Novel Perspectives Toward a Better Understanding of Major Depressive Disorder
- American Psychiatric Association
- View In iTunes
- Jeff & the RPhs
- Jeff and the Pharmacists
- View In iTunes
- PeerView Cardiology CME/CNE/CPE Video Podcast
- PVI, PeerView Institute for Medical Education
- View In iTunes
- eInfluenza Review
- eInfluenza Review
- View In iTunes
